CPNI, Re Judicial Review

Factual and Procedural Background

The applicant, Company A, a company limited by guarantee representing community pharmacy owners in Northern Ireland providing services under the National Health Service, succeeded a prior applicant in a related judicial review. The respondents are the Department of Health Social Services and Public Safety (the Department) and the Health and Social Care Board (the Board). The Department holds statutory duties to maintain and publish a Drug Tariff setting prices and fees for pharmaceutical services, with the Board responsible for arranging service delivery.

Company A challenges determinations under Regulation 9 of the Pharmaceutical Services Regulations (Northern Ireland) 1997 concerning prices and fees in the Drug Tariff, specifically a decision made by the Department on 24 March 2011 to amend the Drug Tariff effective from 1 April 2011.

The background includes a history of market changes in generic drugs since 1999, with government departments in England, Scotland, and Northern Ireland addressing reimbursement discrepancies. Northern Ireland had applied the Scottish tariff model since 2006, supplemented by a compensatory scheme to adjust for local conditions. The 2010 judicial review arose from the Department's attempt to withdraw this compensatory scheme unilaterally.

Following the 2010 judgment, an Interim Agreement was signed in July 2010, setting a stand-alone payment regime for the 2010/11 financial year and outlining consultation and negotiation processes for a lawful Northern Ireland Drug Tariff. Despite extensive consultation and external advice, Company A did not agree to the new Drug Tariff introduced after the Interim Agreement's expiry, contending it failed to provide fair and reasonable remuneration and breached statutory objectives.

Legal Issues Presented

1. Whether the respondents failed to adequately inform themselves by not conducting up-to-date cost and margins surveys prior to introducing the revised Drug Tariff.
2. Whether the Department was obliged to conduct a Regulatory Impact Assessment (RIA) before implementing the amended Drug Tariff and whether failure to do so was a procedural irregularity.
3. Whether the respondents breached procedural fairness by making the impugned determination before the expiry of the relevant consultation period, particularly concerning dispensing fees.

Arguments of the Parties

Applicant's Arguments

• The respondents failed to conduct necessary, up-to-date economic surveys (costs and margins) to inform the Drug Tariff decision, undermining the statutory purpose of ensuring fair remuneration.
• A full Regulatory Impact Assessment was required given the statutory powers exercised and the significant impact on pharmacy businesses; failure to conduct an RIA breached legitimate expectations and procedural fairness.
• The consultation on dispensing fees was prematurely concluded, violating procedural fairness as the decision was made before the consultation period ended.

Respondents' Arguments

• The Department considered no obligation existed to conduct a full RIA as the Drug Tariff was not legislation, did not introduce new regulation, nor change government policy.
• The respondents relied on a high-level economic appraisal using available English data and did not conduct local surveys due to difficulties and lack of cooperation from the applicant.
• The consultation on dispensing fees was conducted separately and fully considered the applicant's representations, with implementation deferred until after consultation completion.

Table of Precedents Cited

Court's Reasoning and Analysis

The court undertook a detailed examination of the statutory framework governing the Drug Tariff, emphasizing the Department's duty to ensure fair and reasonable remuneration for pharmacists in Northern Ireland. It analyzed the evidence regarding the respondents' information-gathering efforts, noting the absence of an up-to-date costs survey and margins survey essential to tailoring the Drug Tariff to local conditions.

The court rejected the respondents' reliance on difficulties and lack of cooperation from the applicant as justification for not using available statutory powers to obtain necessary data, emphasizing that responsibility rested with the public authorities to secure critical information regardless of consultees' cooperation.

Regarding the Regulatory Impact Assessment (RIA), the court found that the Department erroneously disregarded the DETI guidance requiring an RIA for significant regulatory measures affecting businesses. The absence of a full RIA constituted a procedural irregularity, undermining the decision-making process and legitimate expectations.

On consultation, the court distinguished between the Drug Tariff proposals and dispensing fees consultation, finding that the consultation on dispensing fees was prematurely concluded before the expiry of the consultation period, breaching procedural fairness. Although the respondents deferred implementation and considered further representations, the quality of consultation during this period was questioned.

Holding and Implications

The court held the judicial review SUCCESSFUL.

The respondents failed in their statutory duties by not adequately informing themselves through necessary economic surveys, failing to conduct a required Regulatory Impact Assessment, and breaching procedural fairness in consultation on dispensing fees. The decision to introduce the amended Drug Tariff was therefore unlawful.

The court ordered that parties be heard on appropriate relief in light of the judgment. No new precedent was established beyond the direct effect of quashing or invalidating the impugned decision and reinforcing procedural obligations on public bodies in similar regulatory contexts.